For research use only
| Cat No. | ABC-TC0153 |
| Product Type | Human Colon Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Disease | Colon Adenocarinoma |
| Product Code | Colo-206F; Colo 206F; COLO206F; COLO 206; COLO206; Colorado 206F |
COLO-206F Cell Line is a colorectal cancer model used for studying tumor biology, drug sensitivity, and gastrointestinal cancer progression.
The COLO-206F cell line was originally established from the ascites fluid of a 70-year-old male patient with colorectal adenocarcinoma (Dukes Classification Grade D), making it a valuable tool for studying gastrointestinal cancers. These cells exhibit typical malignant characteristics, including rapid proliferation, loss of contact inhibition, and formation of multicellular spheroids in 3D cultures. Morphologically, COLO-206F cells are adherent and suspension-growing epithelial cells with a polygonal or spindle-shaped phenotype. Karyotypic analysis reveals chromosomal instability, a hallmark of colorectal cancer. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | Colo-206F; Colo 206F; COLO206F; COLO 206; COLO206; Colorado 206F |
| Species | Human |
| Cat.No | ABC-TC0153 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Semi-adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Disease | Colon Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
COLO-206F cells are widely used in colorectal cancer research, particularly for investigating tumor progression, metastasis, and drug resistance mechanisms. They serve as an excellent model for preclinical studies, including chemosensitivity assays, targeted therapy development, and biomarker discovery. These cells are also suitable for studying tumor-stroma interactions, angiogenesis, and immune evasion strategies. Their applicability extends to in vivo xenograft models and high-throughput screening platforms for novel anticancer compounds.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
